Showing results (71-80 of 319) with videos related to
Sort By:
Pageof 32
Diseases of the Colon and Rectum|July 21, 2009
A twenty-year experience with adenocarcinoma of the anal canalGeorge J Chang, Ricardo J Gonzalez, John M Skibber, et al.Expert Opinion on Biological Therapy|August 1, 2022
Biologics in rectal cancerAlexandre A Jácome, Renata D'Alpino Peixoto, Mariana V Gil, et al.The Oncologist|May 27, 2025
Biweekly dosing of trifluridine-tipiracil reduces rates of myelosuppression while maintaining efficacy in patients with metastatic colorectal cancerChristopher Cann, Michael LaPelusa, Sarah Cimino, et al.Translational Lung Cancer Research|June 15, 2026
Clinical practice review of systemic treatment in large cell neuroendocrine carcinomaAmanda S Cass, Isabella C Luckage, Albert G Linden, et al.Journal of Pain and Symptom Management|February 9, 2018
The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled TrialSarah Prinsloo, Diane Novy, Larry Driver, et al.Cancer|March 4, 2017
Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot studySarah Prinsloo, Diane Novy, Larry Driver, et al.JCO Oncology Practice|November 14, 2023
Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative TreatmentsEdgardo S Santos, Thomas K Oliver, Christina Lacchetti, et al.Clinical Lung Cancer|March 27, 2019
Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung CarcinoidsBoris G Naraev, Robert A Ramirez, A Tuba Kendi, et al.Cancer|June 8, 2012
Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinomaMoubin Lin, Cathy Eng, Ernest T Hawk, et al.Carcinogenesis|April 17, 2012
GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomesJingyao Dai, Jian Gu, Maosheng Huang, et al.Pageof 32